Should the dose of irinotecan be reduced?
Should UGT1A1 activity or SN-38 serum levels be monitored?
Should the aboslute neutrrophil count be monitored during therapy?
Caution: A qualified health practitioner should verify all results.Keep patient data confidential and comply with all legal requirements.
Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited
Purpose: To evaluate a patient with colorectal adenocarcinoma for therapy with irinotecan (Camptosar) therapy based on UGT1A1 enzyme activity.
Specialty: Toxicology, Emergency Medicine, Critical Care, Genetics
Objective: risk factors, selection